Weight-Loss injections may alter contraception effectiveness

NCT ID NCT07013643

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This early-stage study in 50 healthy women with overweight or obesity examines whether two experimental weight-loss injections, AZD6234 and AZD9550, change how the body processes a common birth control pill. Participants will receive the drugs alone and together, and researchers will measure hormone levels in the blood. The goal is to ensure women using these future treatments can still rely on oral contraception.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD6234 and AZD9550 (injectable drugs for weight loss)
What this could lead to: If successful, this study will show whether these weight-loss drugs change how birth control pills work, helping women choose effective contraception.
What could go wrong: This is an early Phase 1 trial with only 50 healthy participants, so results may not apply to everyone. The study focuses on drug interactions, not on treating a disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS

Contacts and locations

Locations

Research Site
RECRUITING

Glendale, California, 91206, United States
Research Site
RECRUITING

Brooklyn, Maryland, 21225, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.